Repurposing the oncolytic virus VSV∆51M as a COVID-19 vaccine.
Alkayyal AA, Darwish M, Ajina R, Alabbas SY, Alotaibi MA, Alsofyani A, Bokhamseen M, Hakami M, Albaradie OA, Moglan AM, Hala S, Alsahafi AF, Zakri S, Almuzaini A, Alsharari K, Kaboha F, Taher MY, Zein HS, Alroqi F, Mahmoud AB.
Alkayyal AA, et al. Among authors: zakri s.
Front Bioeng Biotechnol. 2023 Jul 17;11:1150892. doi: 10.3389/fbioe.2023.1150892. eCollection 2023.
Front Bioeng Biotechnol. 2023.
PMID: 37528991
Free PMC article.